IQVIA Holdings Inc. (NYSE:IQV) Shares Bought by HighTower Advisors LLC

HighTower Advisors LLC lifted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV – Get Rating) by 30.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 8,290 shares of the medical research company’s stock after acquiring an additional 1,935 shares during the period. HighTower Advisors LLC’s holdings in IQVIA were worth $1,684,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Glassy Mountain Advisors Inc. purchased a new position in IQVIA during the fourth quarter worth about $31,000. Spire Wealth Management lifted its holdings in IQVIA by 40.3% in the fourth quarter. Spire Wealth Management now owns 167 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 48 shares during the last quarter. Hollencrest Capital Management purchased a new position in IQVIA in the fourth quarter worth approximately $41,000. Heritage Wealth Advisors acquired a new stake in IQVIA during the fourth quarter worth $43,000. Finally, Allworth Financial LP raised its position in IQVIA by 36.4% in the fourth quarter. Allworth Financial LP now owns 221 shares of the medical research company’s stock valued at $45,000 after purchasing an additional 59 shares during the period. Institutional investors and hedge funds own 86.20% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on IQV. Stifel Nicolaus decreased their target price on shares of IQVIA from $269.00 to $255.00 in a research report on Friday, April 28th. Barclays dropped their target price on shares of IQVIA from $260.00 to $230.00 and set an “overweight” rating for the company in a report on Tuesday, April 4th. Credit Suisse Group restated an “outperform” rating and set a $265.00 price target on shares of IQVIA in a research note on Monday, February 13th. JPMorgan Chase & Co. lifted their price objective on IQVIA from $257.00 to $263.00 and gave the company an “overweight” rating in a research note on Monday, February 27th. Finally, StockNews.com assumed coverage on IQVIA in a research note on Thursday, May 18th. They set a “hold” rating on the stock. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $253.25.

IQVIA Stock Down 0.3 %

Shares of NYSE:IQV opened at $197.47 on Friday. IQVIA Holdings Inc. has a fifty-two week low of $165.75 and a fifty-two week high of $249.11. The firm’s 50 day moving average price is $194.16 and its 200 day moving average price is $208.10. The company has a quick ratio of 0.80, a current ratio of 0.80 and a debt-to-equity ratio of 1.99. The stock has a market cap of $36.64 billion, a price-to-earnings ratio of 35.52, a price-to-earnings-growth ratio of 1.99 and a beta of 1.39.

IQVIA Profile

(Get Rating)

IQVIA Holdings, Inc engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm’s life science clients.